SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

NASDAQ:SRPT • US8036071004

16.345 USD
-0.42 (-2.48%)
Last: Mar 2, 2026, 11:07 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

SRPT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. SRPT has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • SRPT had negative earnings in the past year.
  • In the past year SRPT has reported a negative cash flow from operations.
  • In the past 5 years SRPT reported 4 times negative net income.
  • In the past 5 years SRPT always reported negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M -600M

1.2 Ratios

  • SRPT has a better Return On Assets (-7.77%) than 85.38% of its industry peers.
  • SRPT's Return On Equity of -20.57% is amongst the best of the industry. SRPT outperforms 82.50% of its industry peers.
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROIC N/A
ROA(3y)-10.59%
ROA(5y)-13.51%
ROE(3y)-36.51%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • With an excellent Gross Margin value of 76.25%, SRPT belongs to the best of the industry, outperforming 84.23% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SRPT has declined.
  • The Profit Margin and Operating Margin are not available for SRPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.08%
GM growth 5Y-6.88%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SRPT has more shares outstanding
  • SRPT has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SRPT has been reduced compared to a year ago.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • Based on the Altman-Z score of -0.15, we must say that SRPT is in the distress zone and has some risk of bankruptcy.
  • SRPT has a Altman-Z score (-0.15) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.78 indicates that SRPT is somewhat dependend on debt financing.
  • The Debt to Equity ratio of SRPT (0.78) is worse than 71.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z -0.15
ROIC/WACCN/A
WACC6.94%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B

2.3 Liquidity

  • SRPT has a Current Ratio of 2.95. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
  • SRPT has a Current ratio of 2.95. This is in the lower half of the industry: SRPT underperforms 64.23% of its industry peers.
  • SRPT has a Quick Ratio of 1.79. This is a normal value and indicates that SRPT is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.79, SRPT is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 1.79
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for SRPT have decreased strongly by -376.32% in the last year.
  • SRPT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.58%.
  • SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.41% yearly.
EPS 1Y (TTM)-376.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-338.67%
Revenue 1Y (TTM)15.58%
Revenue growth 3Y33.07%
Revenue growth 5Y32.41%
Sales Q2Q%-32.73%

3.2 Future

  • Based on estimates for the next years, SRPT will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.03% on average per year.
  • The Revenue is expected to decrease by -7.68% on average over the next years.
EPS Next Y144.16%
EPS Next 2Y55.24%
EPS Next 3Y35.07%
EPS Next 5Y19.03%
Revenue Next Year-25.36%
Revenue Next 2Y-15.7%
Revenue Next 3Y-13.72%
Revenue Next 5Y-7.68%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 5.88, the valuation of SRPT can be described as very cheap.
  • 98.46% of the companies in the same industry are more expensive than SRPT, based on the Price/Forward Earnings ratio.
  • SRPT is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 5.88
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as SRPT's earnings are expected to grow with 35.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y55.24%
EPS Next 3Y35.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SRPT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (3/2/2026, 11:07:05 AM)

16.345

-0.42 (-2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-04
Inst Owners84.9%
Inst Owner Change2.78%
Ins Owners5.13%
Ins Owner Change19.53%
Market Cap1.71B
Revenue(TTM)2.20B
Net Income(TTM)-271.51M
Analysts67.27
Price Target30.93 (89.23%)
Short Float %22.36%
Short Ratio7.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)2.16%
PT rev (3m)-3.44%
EPS NQ rev (1m)-0.54%
EPS NQ rev (3m)8.98%
EPS NY rev (1m)-1.83%
EPS NY rev (3m)-25.86%
Revenue NQ rev (1m)0.23%
Revenue NQ rev (3m)3.29%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)4.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.88
P/S 0.71
P/FCF N/A
P/OCF N/A
P/B 1.3
P/tB 1.33
EV/EBITDA N/A
EPS(TTM)-6.3
EYN/A
EPS(NY)2.78
Fwd EY17.02%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS23.03
BVpS12.6
TBVpS12.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.25%
FCFM N/A
ROA(3y)-10.59%
ROA(5y)-13.51%
ROE(3y)-36.51%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.08%
GM growth 5Y-6.88%
F-Score2
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 290.01%
Cap/Sales 5.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 1.79
Altman-Z -0.15
F-Score2
WACC6.94%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-376.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-338.67%
EPS Next Y144.16%
EPS Next 2Y55.24%
EPS Next 3Y35.07%
EPS Next 5Y19.03%
Revenue 1Y (TTM)15.58%
Revenue growth 3Y33.07%
Revenue growth 5Y32.41%
Sales Q2Q%-32.73%
Revenue Next Year-25.36%
Revenue Next 2Y-15.7%
Revenue Next 3Y-13.72%
Revenue Next 5Y-7.68%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year190.96%
EBIT Next 3Y46.27%
EBIT Next 5Y28.48%
FCF growth 1Y19.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.6%
OCF growth 3YN/A
OCF growth 5YN/A

SAREPTA THERAPEUTICS INC / SRPT FAQ

What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRPT.


Can you provide the valuation status for SAREPTA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Fairly Valued.


What is the profitability of SRPT stock?

SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 2 / 10.


How financially healthy is SAREPTA THERAPEUTICS INC?

The financial health rating of SAREPTA THERAPEUTICS INC (SRPT) is 2 / 10.